Adds glucose monitors to text message diabetes education for type 2 diabetes
Tests text message diabetes education with continuous glucose monitors in adults with type 2 diabetes.
Key facts
- Who runs it
- Scripps Whittier Diabetes Institute
- Where
- San Diego, United StatesSee the site
- Trial code
- Registry title
- Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 3 Apr 2025
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Dulce Digital Text Messaging Intervention
- CGM Device
- Record updated
- 6 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who do not use insulin or a CGM. They get diabetes text messages, and some also wear a CGM for 6 months.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with an A1c between 7.5% (58 mmol/mol) and 12.0% (108 mmol/mol) in the last 90 days.
- Earlier treatment
- Must not be using insulin therapies. Must not be using a CGM now.
- Biomarker or test result
- A1c between 7.5% (58 mmol/mol) and 12.0% (108 mmol/mol) in the last 90 days.
Main reasons for not taking part
- Using insulin therapies
- Pregnant
- Currently using a CGM
- Taking part in another diabetes-related study
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Diagnosed with type 2 diabetes
- Are not currently using a CGM
- Are not using insulin therapies
- Speak English, Spanish or Arabic
- Have A1c between 7.5% and 12.0% in last 90 days
- Have a cellphone that can receive/send text messages and counts steps
Who cannot take part
- Are using insulin therapies
- Are currently using a CGM
- Are currently participating in another diabetes-related study
- Are pregnant
Where in United States
- Scripps Whittier Diabetes InstituteSan Diego, United StatesContact: Athena Philis-Tsimikas, MDTaking people
About the trial
What the trial wants to find out
The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
The 2 groups in the trial
- CGM GroupTreatment being tested
Participants will be provided continuous glucose monitors (Dexcom G7) to monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months).
Treatment: Dulce Digital Text Messaging Intervention and CGM Device
- Usual Care Blood Glucose Monitoring GroupOther group
Participants will use standard blood glucose monitoring devices that are covered by health insurance.
Treatment: Dulce Digital Text Messaging Intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Enhancing Digitally Delivered Diabetes Education With Real-Time CGM: A Comparative Study in People With Type 2 Diabetes
- Plain-language title
- Adds glucose monitors to text message diabetes education for type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 March 2026